Health-related quality of life of patients with HIV: Impact of sociodemographic, clinical and psychosocial factors

Ruiz-Pérez, Isabel; Baño, Jesús Rodríguez; Ruz, Marı́a; Jiménez, Alfonso del Arco; M, Prados; Liaño, Juan Pasquau; Rico, Patricia Martín; Torre, Javier de la; Pardal, José Luis Prada; Gómez, María Ramírez; Muñoz, Nuria Malajovich; Morales, Dolores; Marcos, María Luisa Fernández

doi:10.1007/s11136-004-4715-x

Cited by 107 publications

(107 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…According to Veinot and others [11] and Perez et al [12], patients may feel emotionally unprepared for treatment due to a lack of understanding and/or belief in ART, leading to increased difficulties with everyday treatment management. Therefore, it is crucial to identifying and understanding the difficulties that arise when patients begin to take ARV treatment for this, and will help prevent further episodes of non-adherence and potentially increase long-term adherence with sustainable clinical benefits and improvement in patient quality of life.…”

mentioning

confidence: 99%

An Assessment of the Level of Knowledge of HIV-Infected Patients about Highly Active Antireteroviral Therapy and Waiting Times and Their Influence on Antiretroviral Therapy Adherence at a Primary Healthcare Centre of South Africa

Katende-Kyenda¹,

Apalata²

2017

JPP

View full text Add to dashboard Cite

Abstract:Objectives: The study assessed if the level of knowledge of HIV-infected about HAART and waiting-times in the PHC (primary healthcare) clinic have an influence on antiretroviral adherence. Methods: A descriptive-cross-sectional study was conducted in South Africa. Data collected uses a standardized-questionnaire and face-to-face-exit interviews. Pill-count technique was performed and a value of ≥ 95% acceptable. Data were analysed using SPSS. Univariate-factors associated with poor-adherence to knowledge about HAART and waiting times were assessed using ANOVA and p ≤ 0.05 considered statistically significant. Key findings: Of 86 enrolled, 63(73.3%) were females and 23(26.7%) males, with mean-age (± SD) of 35.6(±9.6) years and on HAART for 35.5(± 31.8) months ranging from 1-137. Of these, 27(31.40%) and 25(29.07%) were on WHO stages 2 and 3 respectively. Adherence-rates computed from 32 patients, 23(71.9%) revealed poor adherence-rates. The level of knowledge about HAART in terms of names of tablets, correct-dose, frequency, adverse-effects had no influence on ARV-adherence (p ≥ 0.05). Of 23 non-compliant, 10 (40%) gave the reason of drugs-unavailability, 7(30%) adverse-effects, 5(20%) drugs' complexity, and 1(10%) too busy to take them. Waiting areas associated with poor ARV-adherence were reception (p = 0.028), doctors (p = 0.027), while nurse's station (p = 0.29) and pharmacy (p = 0.43) revealed acceptable ARV-adherence.

show abstract

mentioning

confidence: 99%

An Assessment of the Level of Knowledge of HIV-Infected Patients about Highly Active Antireteroviral Therapy and Waiting Times and Their Influence on Antiretroviral Therapy Adherence at a Primary Healthcare Centre of South Africa

Katende-Kyenda¹,

Apalata²

2017

JPP

View full text Add to dashboard Cite

show abstract

“…Compared with general population norms, physical and mental HRQOL are lower among persons living with HIV infection. [3][4][5][6][7] In a national probability sample of HIV-infected Americans, physical and mental HRQOL were poorer compared to persons with other chronic diseases. 4 Both mental and physical HRQOL decrease with more advanced stage of disease 3,4 and lower socioeconomic status.…”

mentioning

confidence: 99%

“…4 Both mental and physical HRQOL decrease with more advanced stage of disease 3,4 and lower socioeconomic status. 7 The number of HIV-related symptoms and the presence of comorbid mood disorders have been shown to be strongly associated with lower HRQOL. 5,8 In a cohort of HIV-infected men who have sex with men, patients who were asymptomatic with preserved cellular immunity reported mental HRQOL comparable to the general population, but lower physical scores.…”

mentioning

confidence: 99%

See 1 more Smart Citation

Health-Related Quality of Life in HIV-Infected Patients: The Role of Substance Use

Korthuis

Zephyrin

Fleishman

et al. 2008

AIDS Patient Care and STDs

View full text Add to dashboard Cite

HIV infection and substance use disorders are chronic diseases with complex contributions to health-related quality of life (HRQOL). We conducted a cross-sectional survey of 951 HIV-infected adults receiving care at 14 HIV Research Network sites in 2003 to estimate associations between HRQOL and specific substance use among HIV-infected patients. HRQOL was assessed by multi-item measures of physical and role functioning, general health, pain, energy, positive affect, anxiety, and depression. Mental and physical summary scales were developed by factor analysis. We used linear regression to estimate adjusted associations between HRQOL and current illicit use of marijuana, analgesics, heroin, amphetamines, cocaine, sedatives, inhalants, hazardous/binge alcohol, and drug use severity. Current illicit drug use was reported by 37% of subjects. Mental HRQOL was reduced for current users [adjusted ␤ coefficient Ϫ9.

show abstract

“…Major depression and substance abuse are the two most prevalent psychosocial comorbidities in patients with HIV/AIDS (10)(11)(12), and these problems can interfere with antiretroviral therapy adherence (13)(14)(15)(16)(17)(18). In fact, a significant relationship between adherence to HIV treatment and depression has been reported (19).…”

Section: H Uman Immunodeficiency Virus Infection/aids (Hiv/aids)mentioning

confidence: 99%

Inhibition of Efavirenz Metabolism by Sertraline and Nortriptyline and Their Effect on Efavirenz Plasma Concentrations

Melis

Usach

Gandía

et al. 2016

Antimicrob Agents Chemother

View full text Add to dashboard Cite

Between 22 and 45% of HIV-positive subjects are likely to report symptoms of depression. Considering this background, a potential pharmacokinetic interaction between the nonnucleoside reverse transcriptase inhibitor efavirenz (EFV) and two antidepressants, sertraline (SRT) and nortriptyline (NT), was studied. Rats were administered EFV alone or together with the antidepressants, and changes in the plasma levels and pharmacokinetic parameters of EFV were analyzed. Additional in vitro experiments with rat and human hepatic microsomes were carried out to evaluate the inhibitory effect of SRT and NT on EFV metabolism by determining the formation rate of the major EFV metabolite (8-OH-EFV). In vivo studies showed similar increases in the plasma levels of EFV when it was coadministered with SRT or NT. However, the studies using rat hepatic microsomes showed a more potent inhibitory effect of NT than of SRT on the metabolism of EFV, with values for the 50% inhibition constant (IC 50 ) and inhibitory constant (K i ) for NT about 9-fold lower than those for SRT. An equation was deduced that explains the similar in vivo effects of SRT and NT in spite of the different in vitro performance data. Using human hepatic microsomes, the strongest inhibitory effect was observed with SRT. In summary, pharmacokinetic interactions between EFV, SRT, and NT, associated with the inhibition of hepatic metabolism of EFV, have been detected in rats. Both antidepressants also inhibit EFV metabolism in human hepatic microsomes, but additional in vivo studies in humans are required to evaluate the clinical implication of this interaction. H uman immunodeficiency virus infection/AIDS (HIV/AIDS)is, at present, an incurable disease, and the use of antiretroviral therapy is essential to obtain durable viral suppression, improved immune function, and a good quality of life in infected individuals (1).Current treatment guidelines recommend the use of a drug combination consisting of at least three antiretroviral drugs of multiple classes, known as highly active antiretroviral therapy (HAART). Combining different anti-HIV agents has proven to be beneficial in terms of sustained efficacy and long-term safety, provided there are no significant negative pharmacokinetic drugdrug interactions. At present, preferred regimens of HAART consist of two nucleos(t)ide reverse transcriptase inhibitors (NRTIs) with either a protease inhibitor (PI) or a nonnucleoside reverse transcriptase inhibitor (NNRTI) although other combinations are possible (2, 3).Efavirenz (EFV) is an NNRTI of human immunodeficiency virus type 1 (HIV-1) and is one of the preferred components of first-line antiretroviral regimens. It is widely used as a component of initial HAART (except in infected pregnant women) since it has demonstrated potent and sustained activity in HIV-infected patients as it induces a rapid suppression of the HIV-1 viral load and increases the CD4 cell count (1).In vitro studies with human hepatic microsomes, as well as in vivo studies, have demonstrated that EFV un...

show abstract

Health-related quality of life of patients with HIV: Impact of sociodemographic, clinical and psychosocial factors

Cited by 107 publications

References 32 publications

An Assessment of the Level of Knowledge of HIV-Infected Patients about Highly Active Antireteroviral Therapy and Waiting Times and Their Influence on Antiretroviral Therapy Adherence at a Primary Healthcare Centre of South Africa

An Assessment of the Level of Knowledge of HIV-Infected Patients about Highly Active Antireteroviral Therapy and Waiting Times and Their Influence on Antiretroviral Therapy Adherence at a Primary Healthcare Centre of South Africa

Health-Related Quality of Life in HIV-Infected Patients: The Role of Substance Use

Inhibition of Efavirenz Metabolism by Sertraline and Nortriptyline and Their Effect on Efavirenz Plasma Concentrations

Contact Info

Product

Resources

About